Australia markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
10.40+0.11 (+1.07%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.29
Open10.21
Bid10.35 x 1800
Ask10.41 x 900
Day's range10.21 - 10.46
52-week range8.44 - 13.30
Volume6,080,136
Avg. volume9,485,977
Market cap11.427B
Beta (5Y monthly)1.47
PE ratio (TTM)N/A
EPS (TTM)-3.63
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est11.92
  • Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
    Motley Fool

    Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript

    At this time, I'd like to turn the conference over to Atabak Mokari. Today, we issued three press releases, one announcing the positive outcome of our 178 patients Phase 2 trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. Second, announcing markedly decreased liver fat in patients in our Phase 2 trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis or NASH, and the third, providing a clinical update and announcing our financial results for the first quarter.

  • Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
    Business Wire

    Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the company’s efforts to advance health and equity, minimize its impact on the planet and dedicate itself to quality, ethics and transparency.

  • Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
    Business Wire

    Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States

    Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.